Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 97.6% in January

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant decline in short interest in January. As of January 30th, there was short interest totaling 693,745 shares, a decline of 97.6% from the January 15th total of 29,166,975 shares. Currently, 34.8% of the shares of the company are sold short. Based on an average trading volume of 1,796,547 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 1,796,547 shares, the short-interest ratio is presently 0.4 days. Currently, 34.8% of the shares of the company are sold short.

Institutional Trading of Aspire Biopharma

Several large investors have recently bought and sold shares of ASBP. CIBC Bancorp USA Inc. purchased a new position in shares of Aspire Biopharma in the third quarter valued at $28,000. Jane Street Group LLC increased its holdings in Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after acquiring an additional 131,533 shares in the last quarter. Optivise Advisory Services LLC raised its position in Aspire Biopharma by 120.9% during the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after acquiring an additional 128,660 shares during the last quarter. Finally, Crewe Advisors LLC raised its position in Aspire Biopharma by 100.0% during the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after acquiring an additional 313,427 shares during the last quarter. Institutional investors and hedge funds own 19.17% of the company’s stock.

Analysts Set New Price Targets

ASBP has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, January 21st. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Aspire Biopharma Trading Down 2.1%

ASBP stock opened at $1.41 on Wednesday. The company’s 50-day moving average price is $3.21 and its 200 day moving average price is $10.22. Aspire Biopharma has a 52 week low of $1.26 and a 52 week high of $632.00. The company has a market cap of $3.79 million, a P/E ratio of -0.07 and a beta of 0.81.

Aspire Biopharma (NASDAQ:ASBP) last issued its earnings results on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The business had revenue of $0.00 million for the quarter.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.